Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation.

Authors:
Lennard Glaeser
Lennard Glaeser
University of Tuebingen
Joerg Henes
Joerg Henes
University Hospital Tuebingen
Germany
Wichard Vogel
Wichard Vogel
University of Tübingen
Lothar Kanz
Lothar Kanz
University of Tübingen
Germany
Reinhild Klein
Reinhild Klein
University of Tuebingen

Clin Exp Rheumatol 2018 Feb 13. Epub 2018 Feb 13.

Department of Internal Medicine II, University of Tübingen, Germany.

Objectives: To evaluate the effect of autologous stem cell transplantation (aSCT) on antibody (ab) reactivity towards linear epitopes of topoisomerase-I (topo-I/Scl70) in patients with systemic sclerosis (SSc) and to correlate antibody reactivities with clinical outcome after aSCT.

Methods: Fourteen anti-topo-I/Scl70-positive SSc-patients were analysed before and after non-myeloablative aSCT. Five patients showed ongoing good response (group 1), 9 had primarily responded but later relapsed or did not respond (group 2). Patients' sera were tested by ELISA against full length (fl) topo-I and 45 overlapping 25-mer peptides. Furthermore, for comparison sera from patients with anti-topo-I-negative SSc (n=12), other collagen disorders (n=6), and from 21 healthy controls (HC) were analysed.

Results: Anti-topo-I-positive SSc-sera showed significantly higher IgG-reactivity as compared to HC towards 34 of the 45 peptides. Especially peptide 39 (aa647-671) emerged as a immunodominant epitope being recognised predominantly by anti-topo-I-positive SSc-sera. Reactivity towards 17 of the 45 peptides decreased after aSCT in group 1- and 2-patients. Before aSCT, group 1-patients had lower antibody reactivity towards peptide 39 than group 2-patients. There was no change in peptide-specificity after aSCT.

Conclusions: Reactivity towards topo-I-epitopes is heterogeneous in SSc, but peptide 39 (aa647-671) may be another immunodominant epitope besides the published epitope aa489-573. Antibody reactivity to this peptide 39 was higher in group 2- than in group 1-patients. Peptide recognition pattern did not change after aSCT.
February 2018
6 Reads

Publication Analysis

Top Keywords

antibody reactivity
12
stem cell
8
group 1-patients
8
reactivity peptide
8
patients systemic
8
systemic sclerosis
8
cell transplantation
8
peptide aa647-671
8
anti-topo-i-positive ssc-sera
8
asct group
8
group 2-patients
8
immunodominant epitope
8
autologous stem
8
group
7
reactivity
5
peptide
5
asct
5
elisa full
4
full length
4
length topo-i
4

Similar Publications

Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation.

Rheumatology (Oxford) 2017 03;56(3):451-456

Department of Internal Medicine II, University of Tuebingen, Tuebingen, Germany.

Objectives: To evaluate the effect of autologous stem cell transplantation (aSCTrans) on antibody (Ab) reactivity towards topo I in patients with SSc, and to see whether it may correlate with clinical outcome after aSCTrans.

Methods: Eighteen anti-topo/Scl70-positive patients with SSc in whom non-myeloablative aSCTrans had been performed were analysed. Seven patients showed good response without relapse for several years (group 1), eight primarily responded but later relapsed and three did not respond (group 2). Read More

View Article
March 2017

An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera.

Arthritis Rheum 1999 Jun;42(6):1179-88

University of Pittsburgh School of Medicine, Pennsylvania 15213, USA.

Objective: To characterize an immunodominant epitope recognized by anti-DNA topoisomerase I (topo I) antibody, a major autoantibody in sera of patients with systemic sclerosis (SSc).

Methods: Topo I fragments were generated as fusion proteins using a bacterial expression system as well as polypeptides translated in vitro using a eukaryotic expression system. Reactivities to the 2 preparations of recombinant topo I polypeptides in anti-topo I-positive sera from SSc patients of varied ethnic backgrounds were examined by immunoblotting, immunoprecipitation, and/or enzyme-linked immunosorbent assay. Read More

View Article
June 1999

B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis.

Am J Respir Cell Mol Biol 2000 Mar;22(3):344-51

Department of Organic Chemistry and Biochemistry, School of Natural Sciences, University of Ioannina.

We hypothesized that B-cell epitope mapping of DNA Topoisomerase I (type-I topoisomerase, or Topo I) may define epitopes strongly associated with pulmonary interstitial fibrosis (PIF) in systemic sclerosis (SSc). B-cell epitope mapping of Topo I was performed using 63 20-mer peptides overlapping by eight residues and spanning the entire length of the Topo I sequence. These peptides, coupled to polystyrene pins, were tested for antibody binding by enzyme-linked immunosorbent assays (ELISAs) using immunoglobulin G fractions from anti-Topo I, anticentromere, anti-U3RNP-positive, and normal sera. Read More

View Article
March 2000

Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis.

J Immunol 2004 Aug;173(4):2834-41

Department of Immunology, Division of Rheumatology & Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Autoreactive anti-DNA topoisomerase I (anti-Topo I) Abs are commonly detected in sera of systemic sclerosis (SSc) patients. Our studies have established a positive correlation between the levels of serum anti-Topo I Abs and both disease severity and activity of SSc. The molecular targets of anti-Topo I Ab on Topo I domains remain to be further defined. Read More

View Article
August 2004